1. Clinical pathway interpretation of transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia
- Author
-
Si-Yu YAN, Xing HUANG, Zheng CHEN, Lu YANG, Zhao-Hui JIA, Mou PENG, Xuan-Yi REN, Jing XIONG, Xiao-Dong LI, Xiao-Feng XU, Zhong-Yi SUN, Yong-Bo WANG, Xu-Hui LI, Wan-Li HU, Ting WANG, Ying-Hui JIN, Hao ZI, Tong-Zu LIU, Xian-Tao ZENG, Da-Lin HE, Xing-Huan WANG, Urological Association of Chinese Research Hospital Association, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care, and Project Group for Minimally Invasive Plasmakinetic Surgery System Development and Industrialization of the National Key Research and De-velopment Program
- Subjects
clinical pathway ,benign prostatic hyperplasia ,lower urinary tract symptoms ,tran-surethral plasmakinetic resection ,plasma bipolar resection ,evidence-based medicine ,Medicine - Abstract
Benign prostatic hyperplasia is the most common benign disease that causes urination dysfunction in middle-aged and elderly men, and is also the main cause of lower urinary tract symptoms. Transurethral plasmakinetic resection of prostate has been widely used in clinical practice for its good efficacy and safety. In order to further standardize the clinical application of this surgery, the National Health Commission published the initial Clinical Pathway Interpretation of Transurethral Plasmakinetic Resection of Prostate for Benign Prostatic Hyperplasia in 2019. In view of the limited content of this clinical pathway, using it as a blueprint, we have interpreted it and applied the ideas and methods of evidence-based medicine, aiming to provide a more detailed evidence supplement to help medical staff and managers better understand, grasp and correctly use this clinical pathway.
- Published
- 2022
- Full Text
- View/download PDF